RGIN (Regenicin) Cyclically Adjusted PB Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenicin Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenicin  (OTCPK:RGIN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regenicin Cyclically Adjusted PB Ratio Related Terms


Regenicin Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Regenicin's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin Cyclically Adjusted PB Ratio Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGIN vs NOVNQ, TMBRQ, RGRX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Regenicin's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenicin Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regenicin's Cyclically Adjusted PB Ratio falls into.



Regenicin Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regenicin's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Regenicin's adjusted Book Value per Share data for the three months ended in Mar. 2023 was:

Adj_Book=Book Value per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.04/301.8360*301.8360
=-0.040

Current CPI (Mar. 2023) = 301.8360.

Regenicin Quarterly Data

Book Value per Share CPI Adj_Book
201306 -0.011 233.504 -0.014
201309 -0.036 234.149 -0.046
201312 -0.033 233.049 -0.043
201403 -0.033 236.293 -0.042
201406 -0.034 238.343 -0.043
201409 -0.011 238.031 -0.014
201412 0.005 234.812 0.006
201503 0.008 236.119 0.010
201506 0.005 238.638 0.006
201509 -0.003 237.945 -0.004
201512 -0.008 236.525 -0.010
201603 -0.011 238.132 -0.014
201606 -0.013 241.018 -0.016
201609 -0.010 241.428 -0.013
201612 -0.011 241.432 -0.014
201703 -0.013 243.801 -0.016
201706 -0.015 244.955 -0.018
201709 -0.016 246.819 -0.020
201712 -0.017 246.524 -0.021
201803 -0.019 249.554 -0.023
201806 -0.020 251.989 -0.024
201809 -0.020 252.439 -0.024
201812 -0.021 251.233 -0.025
201903 -0.022 254.202 -0.026
201906 -0.023 256.143 -0.027
201909 -0.024 256.759 -0.028
201912 -0.026 256.974 -0.031
202003 -0.027 258.115 -0.032
202006 -0.028 257.797 -0.033
202009 -0.028 260.280 -0.032
202012 -0.029 260.474 -0.034
202103 -0.030 264.877 -0.034
202106 -0.032 271.696 -0.036
202109 -0.032 274.310 -0.035
202112 -0.033 278.802 -0.036
202203 -0.034 287.504 -0.036
202206 -0.035 296.311 -0.036
202209 -0.036 296.808 -0.037
202212 -0.038 296.797 -0.039
202303 -0.040 301.836 -0.040

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenicin Business Description

Address 10530 Discovery Drive, Las Vegas, NV, USA, 89135
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.